Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
J Med Virol ; 96(6): e29739, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38899449

ABSTRACT

This longitudinal prospective controlled multicenter study aimed to monitor immunity generated by three exposures caused by breakthrough infections (BTI) after COVID-19-vaccination considering pre-existing cell-mediated immunity to common-corona-viruses (CoV) which may impact cellular reactivity against SARS-CoV-2. Anti-SARS-CoV-2-spike-IgG antibodies (anti-S-IgG) and cellular reactivity against Spike-(S)- and nucleocapsid-(N)-proteins were determined in fully-vaccinated (F) individuals who either experienced BTI (F+BTI) or had booster vaccination (F+Booster) compared to partially vaccinated (P+BTI) and unvaccinated (U) from 1 to 24 weeks post PCR-confirmed infection. High avidity anti-S-IgG were found in F+BTI compared to U, the latter exhibiting increased long-lasting pro-inflammatory cytokines to S-stimulation. CoV was associated with higher cellular reactivity in U, whereas no association was seen in F. The study illustrates the induction of significant S-specific cellular responses in F+BTI building-up basic immunity by three exposures. Only U seem to benefit from pre-existing CoV immunity but demonstrated inflammatory immune responses compared to F+BTI who immunologically benefit from enhanced humoral and cellular immunity after BTI. This study demonstrates that individuals with hybrid immunity from COVID-19-vaccination and BTI acquire a stable humoral and cellular immune response that is maintained for at least 6 months. Our findings corroborate recommendations by health authorities to build on basic immunity by three S-protein exposures.


Subject(s)
Antibodies, Viral , COVID-19 Vaccines , COVID-19 , Immunity, Cellular , Immunoglobulin G , SARS-CoV-2 , Spike Glycoprotein, Coronavirus , Humans , COVID-19/immunology , COVID-19/prevention & control , Antibodies, Viral/blood , Antibodies, Viral/immunology , Male , Female , SARS-CoV-2/immunology , Middle Aged , Adult , Prospective Studies , Spike Glycoprotein, Coronavirus/immunology , COVID-19 Vaccines/immunology , COVID-19 Vaccines/administration & dosage , Immunoglobulin G/blood , Longitudinal Studies , Vaccination , Phosphoproteins/immunology , Coronavirus Nucleocapsid Proteins/immunology , Aged , Immunization, Secondary , Cytokines/immunology , BNT162 Vaccine/immunology , BNT162 Vaccine/administration & dosage , 2019-nCoV Vaccine mRNA-1273/immunology , mRNA Vaccines/immunology , Breakthrough Infections
2.
FASEB J ; 31(2): 526-543, 2017 02.
Article in English | MEDLINE | ID: mdl-27825106

ABSTRACT

The response of the skin to harmful environmental agents is shaped decisively by the status of the immune system. Keratinocytes constitutively express and secrete the chemokine-like mediator, macrophage migration inhibitory factor (MIF), more strongly than dermal fibroblasts, thereby creating a MIF gradient in skin. By using global and epidermis-restricted Mif-knockout (Mif-/- and K14-Cre+/tg; Miffl/fl) mice, we found that MIF both recruits and maintains antigen-presenting cells in the dermis/epidermis. The reduced presence of antigen-presenting cells in the absence of MIF was associated with accelerated and increased formation of nonmelanoma skin tumors during chemical carcinogenesis. Our results demonstrate that MIF is essential for maintaining innate immunity in skin. Loss of keratinocyte-derived MIF leads to a loss of control of epithelial skin tumor formation in chemical skin carcinogenesis, which highlights an unexpected tumor-suppressive activity of MIF in murine skin.-Brocks, T., Fedorchenko, O., Schliermann, N., Stein, A., Moll, U. M., Seegobin, S., Dewor, M., Hallek, M., Marquardt, Y., Fietkau, K., Heise, R., Huth, S., Pfister, H., Bernhagen, J., Bucala, R., Baron, J. M., Fingerle-Rowson, G. Macrophage migration inhibitory factor protects from nonmelanoma epidermal tumors by regulating the number of antigen-presenting cells in skin.


Subject(s)
Macrophage Migration-Inhibitory Factors/metabolism , Skin Neoplasms/chemically induced , Skin/cytology , Skin/immunology , Animals , Anthracenes/toxicity , Antigens, CD/genetics , Antigens, CD/metabolism , Carcinogenesis , Gene Expression Regulation/physiology , Inflammation/metabolism , Keratinocytes/metabolism , Macrophage Migration-Inhibitory Factors/genetics , Mice , Mice, Inbred BALB C , Mice, Knockout , Mice, Transgenic , Piperidines/toxicity , Pyridines/toxicity , Receptors, CXCR/genetics , Receptors, CXCR/metabolism
3.
Klin Monbl Augenheilkd ; 219(11): 806-9, 2002 Nov.
Article in German | MEDLINE | ID: mdl-12494372

ABSTRACT

BACKGROUND: Combining pars plana vitrectomy with phacoemulsification and implantation of an intracapsular IOL provides many advantages and is performed as a routine operation. MATERIALS AND METHODS: Over a period of 3 years we compared foldable acrylic lenses AcrySof (Alcon) to heparin-modified PMMA lenses (Pharmacia) in a prospective study. The last implanted lenses had a follow-up period of at least 1 year. Out of 396 eyes from 329 patients we implanted 182 AcrySof lenses and 214 heparin-modified lenses. RESULTS: Both a smaller scleral tunnel incision and a lower rate of secondary cataract are advantages of foldable AcrySof lenses. Higher vulnerability of an AcrySof lens and a less stable lens-iris-diaphragm are of disadvantage. Heparin-modified PMMA lenses do not show these disadvantages, however, in consequence of using them you have to accept the wider scleral tunnel incision and a higher adhesion to cells. Furthermore, we found slightly more posterior synechiae with these lenses. CONCLUSIONS: In all, both types of intraocular lenses are suitable for combined surgery. We recommend using heparin-modified PMMA lenses in case of pre-existent instability of the lens-iris diaphragm or of patients' inability to maintain the prone position.


Subject(s)
Acrylates , Coated Materials, Biocompatible , Heparin , Lenses, Intraocular , Polymethyl Methacrylate , Postoperative Complications/etiology , Vitrectomy , Combined Modality Therapy , Equipment Failure Analysis , Follow-Up Studies , Humans , Prosthesis Design
SELECTION OF CITATIONS
SEARCH DETAIL
...